Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Name: Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Published: 2023
License: Public Domain

Iovance Biotherapeutics, Inc. · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

cell-therapy melanoma

metastatic melanoma, unresectable melanoma, melanoma, tumor infiltrating lymphocytes, til, cell therapy, cellular immuno-therapy, il-2, non-myeloablative lymphodepletion (nmald), check point inhibitor, lifileucel, stage iii melanoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 862642
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.